ST. LOUIS, Mo. – August 8, 2024 – Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that Chief Executive Officer and Co-founder Andrew Barnell, MBA, will attend the following investor conferences:

  • Canaccord Genuity 44th Annual Growth Conference in Boston
    • Fireside Chat on Tuesday, August 13, at 2:00 p.m. ET
  • Morgan Stanley 22nd Annual Global Healthcare Conference in New York City
    • Presentation on Thursday, September 5, at 3:20 p.m. ET
  • Bank of America Healthcare Trailblazers Private Company Conference in Boston on Thursday, September 26

“It’s an honor to present the promising market opportunity of Geneoscopy’s proprietary RNA-based platform,” said Andrew Barnell, CEO and Co-founder of Geneoscopy. “We are proud of our technology’s ability to provide a reliable, scalable, and cost-effective evaluation of RNA biomarkers from stool samples, delivering the ideal platform for developing diagnostic tests to evaluate and improve gastrointestinal health.”

Geneoscopy recently received FDA approval for ColoSense™, a noninvasive colorectal cancer (CRC) screening test. Despite the critical importance of early detection and prevention, more than 44 million average-risk Americans remain unscreened. ColoSense stands out as the only CRC screening test that utilizes RNA biomarkers, which are not subject to age-related patterns that can lead to variability in test performance across different age groups – a challenge for methylation-based assays.1,2

Additionally, Geneoscopy is expanding the use of its proprietary RNA technology to develop diagnostic tests for treatment selection and therapy monitoring for patients with inflammatory bowel disease (IBD). Collaborating with leading pharmaceutical companies and academic institutions, Geneoscopy is striving to deliver promising tools for healthcare providers to aid in predicting and monitoring therapeutic effectiveness for the approximately 3 million Americans who live with IBD.

About Geneoscopy, Inc.

Geneoscopy Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy’s mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company’s FDA-approved ColoSense™ test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other GI disease areas. For more information, visit www.geneoscopy.com and follow the company on LinkedIn.

References:

  1. Ahlquist DA, Taylor WR, Yab TC, et al. Abstract 3572: Methylated gene marker levels in stool: Effects of demographic, drug, and body mass and other patient characteristics. Cancer Research. 2012;72(8_Supplement):3572-3572. https://doi.org/10.1158/1538-7445.am2012-3572
  2. Ahlquist DA, Taylor WR, Yab TC, Devens ME, Mahoney DW, et al. Aberrantly methylated gene marker levels in stool: effects of demographic, exposure, body mass, and other patient characteristics. J Mol Biomark Diagn. 2012;3:133. doi:10.4172/2155-9929.1000133

Media Contact
Andrea Sampson
Sampson Public Relations Group
asampson@sampsonprgroup.com

Investor Contact
Carrie Mendivil / Ji-Yon Yi
Gilmartin Group
investors@geneoscopy.com